Combination of ShuangDan Capsule and Sorafenib Inhibits Tumor Growth and Angiogenesis in Hepatocellular Carcinoma Via PI3K/Akt/mTORC1 Pathway

Hepatocellular carcinoma (HCC) is a high mortality liver cancer. The existing treatments (transplantation, chemotherapy, and individualized treatment) with limitations. However, drug combination provides a viable option for hepatocellular carcinoma treatment. A Chinese patent medicine, ShuangDan Cap...

Full description

Bibliographic Details

Published in:	Integrative Cancer Therapies
Main Authors:	Wenbo Ding PhD, Xiuwei Chen PhD, Licheng Yang Master, Yaping Chen PhD, Jie Song PhD, Weiquan Bu PhD, Bin Feng PhD, Meng Zhang Master, Yi Luo PhD, Xiaobin Jia PhD, Liang Feng PhD
Format:	Article
Language:	English
Published:	SAGE Publishing 2022-03-01
Online Access:	https://doi.org/10.1177/15347354221078888